BillionToOne's ctDNA Monitoring Study Shows Strong Survival Prediction
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 29 2026
0mins
Source: Newsfilter
- Survival Prediction Capability: BillionToOne's Northstar Response® demonstrates superior survival prediction compared to standard imaging in advanced solid tumor patients receiving immunotherapy, with a hazard ratio of 5.3, highlighting its clinical significance.
- Multivariate Analysis Findings: In a cohort of 142 patients, molecular progression emerged as the dominant independent predictor of survival, with a combined risk ratio of 13.8 when paired with imaging assessments, underscoring the clinical value of molecular monitoring.
- Early Cancer Progression Detection: Northstar Response identifies cancer progression an average of 62 days before clinical or radiographic progression, providing oncologists with a potential window to reassess treatment strategies, thereby enhancing patient management effectiveness.
- Technological Innovation and Application: The assay quantifies tumor-specific methylation through simple blood draws, supporting personalized cancer care and showcasing BillionToOne's technological leadership in the molecular diagnostics field.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BLLN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BLLN
Wall Street analysts forecast BLLN stock price to rise
7 Analyst Rating
5 Buy
2 Hold
0 Sell
Moderate Buy
Current: 118.040
Low
110.00
Averages
137.83
High
160.00
Current: 118.040
Low
110.00
Averages
137.83
High
160.00
About BLLN
BillionToOne, Inc. is a precision diagnostics company that quantifies biology to create molecular diagnostics. The Company's proprietary molecular counting platform is designed to detect and measure deoxyribonucleic acid (DNA) molecules at a single-count level to help improve disease detection. It applies the proprietary technology to non-invasive prenatal screening (Prenatal) and liquid biopsy (Oncology). Its Quantitative Counting Templates (QCTs), power its ability to detect and measure tiny and sparse disease-related DNA fragments, or molecules, at the single base-pair level. These include pregnancy-related DNA that code for recessively inherited conditions such as sickle cell disease and cystic fibrosis and ctDNA in the case of cancer. Its prenatal products include UNITY Complete, UNITY Fetal Risk Screen, UNITY Aneuploidy Screen, UNITY Fetal RhD NIPT, UNITY Fetal Antigen NIPT, and UNITY Fetal Antigen CTA NIPT. Its oncology products include Northstar and Northstar Select.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tom Gardner's Five Long-Term Investment Picks
- Portfolio Strategy: Tom Gardner advocates for individual investors to hold at least fifty stocks to navigate the disruptions caused by AI, emphasizing the importance of diversification to mitigate risks and enhance long-term return potential in today's richly priced market.
- Cautious Investment Picks: Gardner's three cautious picks include Cisco Systems, MSCI, and Kingstone Companies, with Cisco boasting $13 billion in free cash flow and double-digit return on assets, while Kingstone has impressively risen from under $1 to $15 per share under strong leadership, showcasing effective management capabilities.
- Moderate Risk Investment: Marvell Technology is identified as a moderate risk option, expected to generate $6 billion in free cash flow in the coming years, with its chips playing a crucial role in rapid data transfer between data centers, potentially positioning it as the next trillion-dollar company.
- Aggressive Investment Opportunity: BillionToOne is classified as an aggressive investment, focusing on advanced genetic testing technologies, with founders possessing strong scientific backgrounds dedicated to identifying minute signals in complex DNA, demonstrating significant market potential and a mission-driven business model.
See More
Tom Gardner's Five Long-Term Stock Picks
- Portfolio Recommendation: Tom Gardner advises that the average investor should own at least fifty stocks to navigate market uncertainties, a viewpoint supported by Peter Lynch's success, emphasizing the importance of diversification in investment strategies.
- AI Transforming Research: Gardner highlights that AI agents are reshaping the investment research landscape, with The Motley Fool making substantial investments in AI scoring systems to identify long-term investment opportunities, showcasing the company's forward-thinking approach to future investment trends.
- Stock Picks: Gardner recommends five stocks, including Cisco Systems (CSCO), MSCI, Kingstone Companies, Marvell Technology, and BillionToOne, spanning a risk spectrum from cautious to aggressive, aimed at helping investors build a diversified long-term portfolio.
- Market Environment Analysis: In the current richly valued market, Gardner suggests that investors adopt cautious and moderate investment strategies, particularly when large IPOs are frequent, indicating a potentially high-risk market environment.
See More
BillionToOne's ctDNA Monitoring Study Shows Strong Survival Prediction
- Survival Prediction Capability: BillionToOne's Northstar Response® demonstrates superior survival prediction compared to standard imaging in advanced solid tumor patients receiving immunotherapy, with a hazard ratio of 5.3, highlighting its clinical significance.
- Multivariate Analysis Findings: In a cohort of 142 patients, molecular progression emerged as the dominant independent predictor of survival, with a combined risk ratio of 13.8 when paired with imaging assessments, underscoring the clinical value of molecular monitoring.
- Early Cancer Progression Detection: Northstar Response identifies cancer progression an average of 62 days before clinical or radiographic progression, providing oncologists with a potential window to reassess treatment strategies, thereby enhancing patient management effectiveness.
- Technological Innovation and Application: The assay quantifies tumor-specific methylation through simple blood draws, supporting personalized cancer care and showcasing BillionToOne's technological leadership in the molecular diagnostics field.
See More
BillionToOne's ctDNA Monitoring Significantly Enhances Survival Prediction
- Enhanced Survival Prediction: BillionToOne's Northstar Response® demonstrated superior survival prediction capabilities compared to standard imaging across 12 tumor types, with a hazard ratio of 5.3 for molecular progression in patients undergoing immunotherapy, highlighting its critical role in cancer treatment.
- Multi-Monitoring Advantage: The combination of Northstar Response with imaging revealed that patients showing disease progression on both assessments had the poorest outcomes, with a hazard ratio of 19.7, underscoring the strategic significance of integrated monitoring in cancer management.
- Early Intervention Window: Northstar Response identified cancer progression an average of 62 days before clinical or radiographic progression, providing oncologists with a crucial opportunity to adjust treatment strategies, potentially improving patient outcomes.
- Clinical Application Prospects: The study emphasizes the importance of continuous molecular monitoring, particularly in immunotherapy patients, enabling earlier identification of treatment response changes and assisting physicians in making more precise treatment decisions.
See More
Dow Jones Futures Flat, Nasdaq Futures Decline Ahead of Jobs Report
- Futures Market Movement: Dow Jones futures remained flat overnight, while S&P 500 and Nasdaq futures declined, reflecting market caution ahead of the upcoming jobs report, which could influence investor sentiment and market direction.
- Jobs Report Anticipation: The market is focused on the May jobs report set to be released before Friday's open, as it is expected to provide crucial insights into the strength of the economic recovery, thereby impacting stock performance and investor decisions.
- IPO Inclusion Standards: S&P Dow Jones Indices announced it will not fast track SpaceX and other upcoming megacap IPOs, such as Anthropic and OpenAI, into the benchmark index, which may affect market performance and investor expectations for these companies.
- Market Reaction Analysis: Given the sensitivity to employment data, investors may adopt a wait-and-see approach before the report's release, potentially leading to increased volatility in the market, particularly among tech stocks and those related to large IPOs.
See More
Dow Jones Futures Steady, S&P 500 and Nasdaq Futures Decline Modestly
- Futures Market Movement: Dow Jones futures remained little changed in after-hours trading, while S&P 500 and Nasdaq futures experienced modest declines, reflecting market caution ahead of upcoming economic data, particularly the May jobs report.
- Jobs Report Anticipation: The market is keenly awaiting the May jobs report set to be released before Friday's open, as investors look to gauge the strength of the economic recovery and its implications for future monetary policy.
- IPO Inclusion Standards: S&P Dow Jones Indices announced late Thursday that it will not fast-track SpaceX and other upcoming megacap IPOs, such as Anthropic and OpenAI, into the benchmark index, which may impact market performance and investor confidence in these companies.
- Market Sentiment Analysis: Given the anticipation surrounding employment data and changes in IPO inclusion standards, market sentiment remains cautious, with investors likely adopting a wait-and-see approach to assess future investment opportunities.
See More
Tom Gardner's Five Long-Term Investment Picks
- Portfolio Strategy: Tom Gardner advocates for individual investors to hold at least fifty stocks to navigate the disruptions caused by AI, emphasizing the importance of diversification to mitigate risks and enhance long-term return potential in today's richly priced market.
- Cautious Investment Picks: Gardner's three cautious picks include Cisco Systems, MSCI, and Kingstone Companies, with Cisco boasting $13 billion in free cash flow and double-digit return on assets, while Kingstone has impressively risen from under $1 to $15 per share under strong leadership, showcasing effective management capabilities.
- Moderate Risk Investment: Marvell Technology is identified as a moderate risk option, expected to generate $6 billion in free cash flow in the coming years, with its chips playing a crucial role in rapid data transfer between data centers, potentially positioning it as the next trillion-dollar company.
- Aggressive Investment Opportunity: BillionToOne is classified as an aggressive investment, focusing on advanced genetic testing technologies, with founders possessing strong scientific backgrounds dedicated to identifying minute signals in complex DNA, demonstrating significant market potential and a mission-driven business model.
See More
Tom Gardner's Five Long-Term Stock Picks
- Portfolio Recommendation: Tom Gardner advises that the average investor should own at least fifty stocks to navigate market uncertainties, a viewpoint supported by Peter Lynch's success, emphasizing the importance of diversification in investment strategies.
- AI Transforming Research: Gardner highlights that AI agents are reshaping the investment research landscape, with The Motley Fool making substantial investments in AI scoring systems to identify long-term investment opportunities, showcasing the company's forward-thinking approach to future investment trends.
- Stock Picks: Gardner recommends five stocks, including Cisco Systems (CSCO), MSCI, Kingstone Companies, Marvell Technology, and BillionToOne, spanning a risk spectrum from cautious to aggressive, aimed at helping investors build a diversified long-term portfolio.
- Market Environment Analysis: In the current richly valued market, Gardner suggests that investors adopt cautious and moderate investment strategies, particularly when large IPOs are frequent, indicating a potentially high-risk market environment.
See More
BillionToOne's ctDNA Monitoring Study Shows Strong Survival Prediction
- Survival Prediction Capability: BillionToOne's Northstar Response® demonstrates superior survival prediction compared to standard imaging in advanced solid tumor patients receiving immunotherapy, with a hazard ratio of 5.3, highlighting its clinical significance.
- Multivariate Analysis Findings: In a cohort of 142 patients, molecular progression emerged as the dominant independent predictor of survival, with a combined risk ratio of 13.8 when paired with imaging assessments, underscoring the clinical value of molecular monitoring.
- Early Cancer Progression Detection: Northstar Response identifies cancer progression an average of 62 days before clinical or radiographic progression, providing oncologists with a potential window to reassess treatment strategies, thereby enhancing patient management effectiveness.
- Technological Innovation and Application: The assay quantifies tumor-specific methylation through simple blood draws, supporting personalized cancer care and showcasing BillionToOne's technological leadership in the molecular diagnostics field.
See More
BillionToOne's ctDNA Monitoring Significantly Enhances Survival Prediction
- Enhanced Survival Prediction: BillionToOne's Northstar Response® demonstrated superior survival prediction capabilities compared to standard imaging across 12 tumor types, with a hazard ratio of 5.3 for molecular progression in patients undergoing immunotherapy, highlighting its critical role in cancer treatment.
- Multi-Monitoring Advantage: The combination of Northstar Response with imaging revealed that patients showing disease progression on both assessments had the poorest outcomes, with a hazard ratio of 19.7, underscoring the strategic significance of integrated monitoring in cancer management.
- Early Intervention Window: Northstar Response identified cancer progression an average of 62 days before clinical or radiographic progression, providing oncologists with a crucial opportunity to adjust treatment strategies, potentially improving patient outcomes.
- Clinical Application Prospects: The study emphasizes the importance of continuous molecular monitoring, particularly in immunotherapy patients, enabling earlier identification of treatment response changes and assisting physicians in making more precise treatment decisions.
See More
Dow Jones Futures Flat, Nasdaq Futures Decline Ahead of Jobs Report
- Futures Market Movement: Dow Jones futures remained flat overnight, while S&P 500 and Nasdaq futures declined, reflecting market caution ahead of the upcoming jobs report, which could influence investor sentiment and market direction.
- Jobs Report Anticipation: The market is focused on the May jobs report set to be released before Friday's open, as it is expected to provide crucial insights into the strength of the economic recovery, thereby impacting stock performance and investor decisions.
- IPO Inclusion Standards: S&P Dow Jones Indices announced it will not fast track SpaceX and other upcoming megacap IPOs, such as Anthropic and OpenAI, into the benchmark index, which may affect market performance and investor expectations for these companies.
- Market Reaction Analysis: Given the sensitivity to employment data, investors may adopt a wait-and-see approach before the report's release, potentially leading to increased volatility in the market, particularly among tech stocks and those related to large IPOs.
See More
Dow Jones Futures Steady, S&P 500 and Nasdaq Futures Decline Modestly
- Futures Market Movement: Dow Jones futures remained little changed in after-hours trading, while S&P 500 and Nasdaq futures experienced modest declines, reflecting market caution ahead of upcoming economic data, particularly the May jobs report.
- Jobs Report Anticipation: The market is keenly awaiting the May jobs report set to be released before Friday's open, as investors look to gauge the strength of the economic recovery and its implications for future monetary policy.
- IPO Inclusion Standards: S&P Dow Jones Indices announced late Thursday that it will not fast-track SpaceX and other upcoming megacap IPOs, such as Anthropic and OpenAI, into the benchmark index, which may impact market performance and investor confidence in these companies.
- Market Sentiment Analysis: Given the anticipation surrounding employment data and changes in IPO inclusion standards, market sentiment remains cautious, with investors likely adopting a wait-and-see approach to assess future investment opportunities.
See More
